Intravenous (IV) Lidocaine for Opioid-refractory Pain

• Status: Withdrawn
• Trial end date: 2009-05-01
• Target enrollment: 0
• Participant gender: All

Summary

Opioid medicines, like morphine, are the main treatment for severe cancer pain. Unfortunately, some patients suffer severe pain despite high doses of opioids. We hypothesize that intravenous lidocaine can quickly and effectively treat this kind of opioid-refractory pain.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: San Diego Hospice & Palliative Care
• Treatments: Lidocaine

Criteria

Inclusion Criteria

• Advanced cancer patient (prognosis ≤6 mos)

• Age ≥ 18 years old

• Opioid-refractory pain

• Steady state levels of adjunctive pain medications

• Intravenous access

• Has decision-making capacity

• Hemodynamics: 85- EKG QTc ≤ 440 msec

Exclusion Criteria

• Methadone use

• Myoclonus

• Seizure disorder

• History of ventricular arrhythmia

• Allergy to amide local anesthetics

• Evidence of cardiac ischemia by history or EKG

• Currently receiving a parenteral local anesthetic

• Pregnancy